Landrum, L. M., Brady, W. E., Armstrong, D. K., Moore, K. N., DiSilvestro, P. A., O'Malley, D. M., . . . Fracasso, P. M. (2015). A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin, Bevacizumab and Veliparib in Recurrent, Platinum-Sensitive Ovarian, Primary Peritoneal, and Fallopian Tube Cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol.

Landrum, Lisa M., William E. Brady, Deborah K. Armstrong, Kathleen N. Moore, Paul A. DiSilvestro, David M. O'Malley, Meaghan E. Tenney, Peter G. Rose, a Paula M. Fracasso. "A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin, Bevacizumab and Veliparib in Recurrent, Platinum-Sensitive Ovarian, Primary Peritoneal, and Fallopian Tube Cancer: An NRG Oncology/Gynecologic Oncology Group Study." Gynecol Oncol 2015.

Landrum, Lisa M., et al. "A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin, Bevacizumab and Veliparib in Recurrent, Platinum-Sensitive Ovarian, Primary Peritoneal, and Fallopian Tube Cancer: An NRG Oncology/Gynecologic Oncology Group Study." Gynecol Oncol 2015.